The SWOG S1011 trial shows no survival benefit from extended lymphadenectomy in bladder cancer, revealing higher complications and mortality post-surgery.
Eligible patients had urothelial cancer of clinical stage ... of T4b tumor status or metastasis (in 6), no muscle-invasive bladder cancer (in 8), a lack of pretrial scans (in 1), and randomization ...
TORONTO, ON / ACCESSWIRE / October 7, 2024 / Theralase® Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development ...
the Foundation of Urological Research (Ove and Carin Carlsson bladder cancer donation), and Hillevi Fries Research Foundation. The funding sources had no role in the study design, data analyses, ...